{"id":"W2024010256","doi":"10.1517/14712598.2013.770835","title":"Vedolizumab for Crohn's disease","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; Robarts Clinical Trials","funders":"","keywords":"Vedolizumab; Medicine; Crohn's disease; Expert opinion; Adverse effect; Disease; Ustekinumab; Inflammatory bowel disease; Prednisone; Monoclonal antibody; Placebo; Intensive care medicine; Immunology; Internal medicine; Infliximab; Antibody; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003497027,0.00047204,0.0008797516,0.001191298,0.000172308,0.0005855321,0.0005993153,0.0008811812,0.004575649],"category_scores_gemma":[0.0004163125,0.0001270094,0.0004149424,0.0008675506,0.0002773046,0.0005874797,0.0003926653,0.001298814,0.002750609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004280117,"about_ca_system_score_gemma":0.0004946617,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006504408,"about_ca_topic_score_gemma":0.001534957,"domain_scores_codex":[0.9998373,0.00003313489,0.00001971325,0.00002870751,0.0000656435,0.00001546132],"domain_scores_gemma":[0.9998595,0.00005418801,0.00003254027,0.000003438234,0.00003501618,0.00001532116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009467009,0.00003392159,0.000082346,0.01275688,0.00008578871,0.000283891,0.00003043146,0.0001771236,0.002027902,0.002007716,0.04388779,0.9385315],"study_design_scores_gemma":[0.00005580984,0.00008955812,0.000505317,0.004441371,0.0001109546,0.002197174,0.00002653647,0.00008182489,0.000453638,0.001335297,0.9906898,0.0000127643],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001566826,0.9968664,0.0001357583,0.0005669598,0.000358834,0.000007915574,0.00002402745,0.00000884004,0.001874497],"genre_scores_gemma":[0.001543853,0.9959862,0.0002119205,0.0005588469,0.0003193694,0.00001017341,0.00005551295,0.000002107869,0.001312004],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004575649,"threshold_uncertainty_score":0.01530707,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.124737181594895,"score_gpt":0.3899971346007448,"score_spread":0.2652599530058498,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}